Cantor Fitzgerald Initiates Coverage of Pelthos Therapeutics (PTHS) with Overweight Recommendation

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks PTHS Cantor Fitzgerald Initiates Coverage of Pelthos Therapeutics (PTHS) with Overweight Recommendation April 02, 2026 — 08:04 pm EDT Written by George Maybach for Fintel-> Fintel reports that on April 1, 2026, Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) with a Overweight recommendation.

Analyst Price Forecast Suggests 191.67% Upside As of March 27, 2026, the average one-year price target for Pelthos Therapeutics is $59.50/share. The forecasts range from a low of $48.48 to a high of $78.75. The average price target represents an increase of 191.67% from its latest reported closing price of $20.40 / share. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Pelthos Therapeutics is 66MM, an increase of 291.78%. The projected annual non-GAAP EPS is -1.07. What is the Fund Sentiment? There are 20 funds or institutions reporting positions in Pelthos Therapeutics. This is an increase of 2 owner(s) or 11.11% in the last quarter. Average portfolio weight of all funds dedicated to PTHS is 0.16%, an increase of 63.43%. Total shares owned by institutions increased in the last three months by 94.35% to 899K shares. What are Other Shareholders Doing? Murchinson holds 289K shares representing 8.63% ownership of the company. In its prior filing, the firm reported owning 280K shares , representing an increase of 3.27%. The firm increased its portfolio allocation in PTHS by 45.16% over the last quarter. Ikarian Capital holds 256K shares representing 7.62% ownership of the company. In its prior filing, the firm reported owning 62K shares , representing an increase of 75.58%. The firm increased its portfolio allocation in PTHS by 250.58% over the last quarter.

Boothbay Fund Management holds 81K shares representing 2.40% ownership of the company. In its prior filing, the firm reported owning 21K shares , representing an increase of 73.67%. The firm increased its portfolio allocation in PTHS by 331.14% over the last quarter. J. Goldman & Co holds 78K shares representing 2.32% ownership of the company. Cantor Fitzgerald, L. P. holds 35K shares representing 1.04% ownership of the company. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Click to Learn MoreThis story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags Stocks Fintel Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford. Check out our Unique Analysis of Insider Sentiment for Pelthos Therapeutics Inc.-> Find out what the Options Markets think of Pelthos Therapeutics Inc.-> See our take on Pelthos Therapeutics Inc. Upcoming Earnings-> More articles by this source-> Stocks mentioned PTHS More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.